Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
D000818:Animals; D000942:Antigens, Bacterial; D001500:BCG Vaccine / Q000627:therapeutic use*; D001580:Benzopyrenes; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D005472:Fluorouracil / Q000627:therapeutic use; D007111:Immunity, Cellular; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000382:microbiology / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008324:Mammary Tumor Virus, Mouse / Q000302:isolation & purification; D008727:Methotrexate / Q000627:therapeutic use; D008748:Methylcholanthrene; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009163:Mycobacterium bovis / Q000276:immunology*; D009368:Neoplasm Transplantation; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D013852:Thiotepa / Q000627:therapeutic use; D014184:Transplantation, Homologous; D014747:Vinblastine / Q000627:therapeutic use
D000942:Antigens, Bacterial; D001500:BCG Vaccine; D001580:Benzopyrenes; D008748:Methylcholanthrene; D014747:Vinblastine; D003520:Cyclophosphamide; D013852:Thiotepa; D005472:Fluorouracil; D008727:Methotrexate